Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
See Latest ArticlesIdentification, characterization, and biological relevance of prostate cancer stem cells from clinical specimens
Urologic Oncology: Seminars and Original Investigations, 06/30/09
Kasper S - Cancer stem cells (CSCs) are a reservoir of tumor cells that exhibit the properties of self-renewal and the ability to re-establish the heterogeneous cell population of a tumor. They appear therapy-resistant and may be the underlying cause of recurrent disease.
Related Articles
Stem cell therapy for age-related retinal disease
Aging Health, 11/23/09
Relevance Score: 70%
Plerixafor hydrochloride: A novel agent for the mobilization of peripheral blood stem cells
Drugs of Today, 11/05/09
Relevance Score: 70%
Neural stem cell therapy in neurological diseases
Archives of Medical Science, 11/02/09
Relevance Score: 70%
The cancer stem cell microenvironment and anti-cancer therapy
International Journal of Radiation Biology, 11/05/09
Relevance Score: 69%
Autologous Fibrin-Cultured Limbal Stem Cells Permanently Restore the Corneal Surface of Patients With Total Limbal Stem Cell Deficiency
Transplantation, 10/06/09
Relevance Score: 69%
Today in Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/04/09
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09
The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
Cancer Treatment Reviews, 12/04/09
Today in Prostate...keeping you current
Receive free subspecialty "5-minute updates" via email
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09
The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
Cancer Treatment Reviews, 12/04/09
Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature
European Urology, 12/04/09
Article Search
Sponsor